Clinical and pathological characteristics of lung cáncer.

Características clínicas y patológicas de cáncer de pulmón.

Main Article Content

Pedro Luis Ramos Guette
María Athenas Ramos
Diana Silva
Abstract

Introduction and objective: Lung cancer is the leading cause of incidence and mortality in the world. The main purpose of this study is to describe the clinical and pathological characteristics of lung cancer patients, their overall survival and progression-free survival. Materials and methods: This is a descriptive, observational and retrospective study realized with lung cancer patients during the time period of 1 of January 2005 to 21 of March 2016. Descriptive analysis were preformed using central tendency, location and dispersion methods for continuous variables and absolute and relative frequencies for categorical variables and survival curves with the Kaplan-Meier method. Results: 224 patients were identified with an average age of 65 years old and 52% were males. Their clinical stage was IIB and IV in 83% of them, 58% had functional stage ECOG 0-1. 20% had cerebral metastasis, histologically 65% were adenocarcinomas and 12% were EGFR positive. The median overall survival was 18.9 months for advanced cases (IIIB y IV) and progression-free survival was 11.6 months. Conclusions: In this study the average age was 65 years old, the most common histology type was adenocarcinoma, and 12% had the mutation for the EGF receptor and survival was similar than the one found in medical literature.

Keywords

Downloads

Download data is not yet available.

Article Details

Author Biographies (SEE)

Pedro Luis Ramos Guette, Clínica Oncocare

Oncólogo clínico, Clínica Oncocare

María Athenas Ramos, Clínica Oncocare

Estudiante Medicina, grupo de investigación oncocare

Diana Silva, Clínica Oncocare

Enfermera oncóloga, grupo de investigación oncocare

References

International Agency for Research on Cancer. Globocan 2018 [internet]. [cited 2018 Sep]. Disponible en: http://globocan.iarc.fr/

Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311(7010):899-909.

NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced nonsmall-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617-25.

Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374 (9699):1432-40.

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20-30.

Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277-83.

Rossi A, Chiodini P, Sun JM, O’Brien ME, von Plessen C, Barata F, et al. Six versus fewer planned cycles of first-line platinumbased chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014;15(11):1254-62.

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-74.

Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cáncer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595-605.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cáncer (Optimal, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-42.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (Optimal, CTONG-0802). Ann Oncol. 2015;26 (9):1877-83.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label Keynote-021 study. Lancet Oncol. 2016;17 (11):1497-1508.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387-401.

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-37.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-51.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (Keynote-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-30.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised Recist guideline (versión 1.1). Eur J Cancer. 2009;45(2):228-47.

OJS System - Metabiblioteca |